Stockreport

Emerging Data for Lantern Pharma's Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failur...

Lantern Pharma Inc.  (LTRN) 
PDF Among L858R patients in HARMONICâ„¢, those who completed 6 doses or cycles of LP-300 demonstrated a higher median PFS than the overall L858R cohort and those patients tha [Read more]